According to Ethan Mollick on X, AI models show steady gains on medical benchmarks and in studies with real cases and physicians, with many tasks where current systems meet or exceed clinician performance; however, there are still few rigorous evaluations of real-world deployment outcomes in medicine, highlighting an evidence gap between lab results and clinical impact (as reported by Ethan Mollick, citing cross-benchmark trends). According to peer-reviewed literature summarized by Nature Medicine and The Lancet Digital Health, benchmark superiority does not consistently translate into improved patient outcomes without workflow integration, prospective trials, and monitoring, underscoring the need for pragmatic clinical studies and post-market surveillance. For health systems and AI vendors, the business opportunity centers on validated pathways—prospective impact trials, bias and safety auditing, and integration into EHR and triage workflows—to convert benchmark wins into reimbursable, outcome-improving solutions.

According to Greg Brockman on X, ChatGPT assisted a cancer patient named Sid in identifying additional treatment options after clinicians said no options remained, highlighting generative AI’s potential in patient-centric care navigation (source: Greg Brockman, X, Mar 21, 2026). As reported by Greg Brockman, the case underscores how large language models can synthesize clinical guidance, surface clinical trials, and support second-opinion workflows when paired with verified medical sources and clinician oversight (source: Greg Brockman, X). According to industry best practices cited by OpenAI and healthcare AI deployments, the commercial opportunity lies in building regulated copilots that integrate with EHRs, NCCN and FDA-approved therapies, and clinical trial registries, with audit logs and guardrails for safety (source: OpenAI system card statements and documented healthcare integrations referenced in OpenAI developer materials).